A Phase II Trial of Dual Protease Inhibitor Therapy: Amprenavir in Combination With Indinavir, Nelfinavir, or Saquinavir
This study evaluated dual protease inhibitor (PI) regimens containing amprenavir (APV) in Pi-naive, HIV-1-infected patients over 48 weeks. Patients were randomized to 800-mg APV combined with 800-mg indinavir (IDV), 750-mg nelfi navir (NFV), or 800-mg saquinavir-soft gel capsule (SGV-SGC), all three...
Gespeichert in:
Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 2001-04, Vol.26 (5), p.458-461 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | This study evaluated dual protease inhibitor (PI) regimens containing amprenavir (APV) in Pi-naive, HIV-1-infected patients over 48 weeks. Patients were randomized to 800-mg APV combined with 800-mg indinavir (IDV), 750-mg nelfi navir (NFV), or 800-mg saquinavir-soft gel capsule (SGV-SGC), all three times daily without nucleoside reverse transcriptase inhibitors, or APV given alone for 3 weeks and then with 150-mg lamivudine (3TC) and 300-mg zidovudine (ZDV), twice daily. Dual PI therapy demonstrated substantial antiviral activity and was generally safe and well tolerated. Eight patients had virologic failure; 5 were receiving dual PI therapy and 3 were in the APV/3TC/ZDV arm. The protease I50V mutation characteristic of APV resistance was not observed, although other key PI mutations were selected in 4 patients failing therapy, 2 of whom had PI resistance at baseline. |
---|---|
ISSN: | 1525-4135 1944-7884 |
DOI: | 10.1097/00042560-200104150-00008 |